This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
When dosed every 7 or 14 days, IDELVION had a zero median annualized spontaneous and joint bleeding rate.
When dosed at 7 days, IDELVION had an interquartile range, or IQR, of 0 to 0 spontaneous and joint bleeds (IQR at 14 days was 0 to 1 for spontaneous bleeds and 0 to 1.04 for joint bleeds). IQR looks at the middle 50% of people in a clinical study.
IDELVION is the only FDA-approved Factor IX therapy that lets some people go up to two weeks between doses—while still maintaining high factor levels and prolonged bleed protection. Explore what 14-day* dosing with IDELVION can do.
*Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
IDELVION delivered high and sustained factor trough levels—20% with prophylactic use at steady state† when dosed every 7 days.
†Steady state is a consistent and uniform amount of factor in the body from continued use.
‡The average dose for people receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.
§The average dose for children receiving prophylaxis every 7 days was 47 IU/kg.
Trough levels are the low point factor levels reach shortly before a new dose. Having high factor levels even at the lowest point between doses means you’re better protected even when you’re most vulnerable.
IDELVION extends half-life using
albumin fusion technology
Real people sharing their
experiences with IDELVION
